SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's inches up on launching Propofol Injectable Emulsion in US market

24 Jan 2019 Evaluate

Dr. Reddys Laboratories is currently trading at Rs. 2663.05, up by 17.55 points or 0.66% from its previous closing of Rs. 2645.50 on the BSE.

The scrip opened at Rs. 2640.00 and has touched a high and low of Rs. 2670.35 and Rs. 2640.00 respectively. So far 10464 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2745.00 on 03-Dec-2018 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2670.35 and Rs. 2585.00 respectively. The current market cap of the company is Rs. 44271.00 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.67% and 13.94% respectively.

Dr. Reddy's Laboratories has launched Propofol Injectable Emulsion, USP, a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, USP, approved by the US Food and Drug Administration (USFDA).

According to IMS Health, the Diprivan brand and generic had U.S. sales of approximately $310 million MAT for the most recent twelve months ending in November 2018. The company's Propofol Injectable Emulsion, USP is available in 10 mg/ml vials for single patient use only. 

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1235.40 14.15 (1.16%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×